サマリー

市場分析と洞察。腎細胞性嚢腫治療薬の世界市場
COVID-19の流行により、腎細胞癌治療薬の世界市場規模は2022年には100万米ドルと推定され、2028年には再調整後の市場規模が100万米ドルになると予測されています。この健康危機による経済的変化を十分に考慮し、2021年にはSutent（Sunitinib）が腎細胞癌治療薬の世界市場の%を占めていましたが、COVID-19後の期間には改訂された%のCAGRで成長し、2028年には100万米ドルになると予測されています。一方、MTSCC（Mucinous Tubular and Spindle Cell Carcinoma）セグメントは、この予測期間を通して％CAGRに変更されています。
中国の腎細胞癌治療薬の市場規模は2021年に百万米ドル、米国と欧州の腎細胞癌治療薬の市場規模はそれぞれ百万米ドルと百万米ドルとなっています。2021年の米国の割合は%で、中国と欧州はそれぞれ%と%で、中国の割合は2028年に%に達し、分析期間中のCAGRは%になると予測されています。アジアでは、日本、韓国、東南アジアが注目すべき市場であり、今後6年間のCAGRはそれぞれ％、％、％となっています。欧州の腎細胞癌治療薬市場では、ドイツが2028年までに100万米ドルに達すると予測されており、予測期間中のCAGRは%となっています。
腎細胞癌治療薬の世界的な主要メーカーには、Merck & Co., Inc.、Exelixis Inc.、Argus Therapeutics, Inc.、Bristol-Myers Squibb、Genentech、Immatics Biotechnologies、AVEO Oncology、Eisai、Acceleronなどがあります。2021年には、世界の上位5社の売上高シェアは約%となっています。
世界の腎細胞癌治療薬のスコープとセグメント
腎細胞性嚢腫治療薬市場は、タイプ別、アプリケーション別に分類されています。世界のRenal Cell Cacinoma Drugs市場のプレーヤー、ステークホルダー、その他の参加者は、本レポートを強力なリソースとして活用することで、優位に立つことができるでしょう。セグメント分析では、2017年から2028年の期間におけるタイプ別、アプリケーション別の売上高、収益、予測に焦点を当てています。
タイプ別セグメント
Sutent(Sunitinib)
Nexavar(Sorafenib)
Votrient（Pazopanib)
Avastin(Bevacizumab)
アフィニトール(エベロリムス)
インライタ(アキシチニブ)
トリセル(テムシロリムス)
プロロイキン(アルデスロイキン)
用途別セグメント
粘液管状および紡錘細胞がん（MTSCC）
多包性嚢胞性透明細胞腎細胞癌
管状嚢胞性腎細胞癌（Tubulocystic Renal Cell Carcinoma
甲状腺様濾胞性腎細胞癌（Thyroid-like Follicular Renal Cell Carcinoma
その他
会社別
メルク・アンド・カンパニー・インク
エクセリクシス社
アーガス・セラピューティクス社（Argus Therapeutics, Inc.
ブリストル・マイヤーズ スクイブ（Bristol-Myers Squibb
ジェネンテック
イマティクスバイオテクノロジーズ
AVEOオンコロジー
エーザイ
アクセロン
レクサーン・ファーマシューティカルズ
バイオノミクス
セルリアン・ファーマ・インク
セルデックス・セラピューティクス（Celldex Therapeutics
TVAXバイオメディカル
トラコン・ファーマシューティカルズ
地域別
北アメリカ
米国
カナダ
ヨーロッパ
ドイツ
フランス
イギリス
イタリア
ロシア
アジアパシフィック
中国
日本
韓国
インド
オーストラリア
台湾
インドネシア
タイ
マレーシア
フィリピン
ベトナム
ラテンアメリカ
メキシコ
ブラジル
アルゼンチン
中近東・アフリカ
トルコ
サウジアラビア
UAE

ページTOPに戻る

目次

1 Study Coverage
1.1 Renal Cell Cacinoma Drugs Product Introduction
1.2 Market by Type
1.2.1 Global Renal Cell Cacinoma Drugs Market Size Growth Rate by Type, 2017 VS 2021 VS 2028
1.2.2 Sutent(Sunitinib)
1.2.3 Nexavar(Sorafenib)
1.2.4 Votrient(Pazopanib)
1.2.5 Avastin(Bevacizumab)
1.2.6 Afinitor(Everolimus)
1.2.7 Inlyta(Axitinib)
1.2.8 Torisel(Temsirolimus)
1.2.9 Proleukin(Aldesleukin)
1.3 Market by Application
1.3.1 Global Renal Cell Cacinoma Drugs Market Size Growth Rate by Application, 2017 VS 2021 VS 2028
1.3.2 Mucinous Tubular and Spindle Cell Carcinoma (MTSCC)
1.3.3 Multilocular Cystic Clear Cell Renal Cell Carcinoma
1.3.4 Tubulocystic Renal Cell Carcinoma
1.3.5 Thyroid-Like Follicular Renal Cell Carcinoma
1.3.6 Others
1.4 Study Objectives
1.5 Years Considered
2 Executive Summary
2.1 Global Renal Cell Cacinoma Drugs Sales Estimates and Forecasts 2017-2028
2.2 Global Renal Cell Cacinoma Drugs Revenue Estimates and Forecasts 2017-2028
2.3 Global Renal Cell Cacinoma Drugs Revenue by Region: 2017 VS 2021 VS 2028
2.4 Global Renal Cell Cacinoma Drugs Sales by Region
2.4.1 Global Renal Cell Cacinoma Drugs Sales by Region (2017-2022)
2.4.2 Global Sales Renal Cell Cacinoma Drugs by Region (2023-2028)
2.5 Global Renal Cell Cacinoma Drugs Revenue by Region
2.5.1 Global Renal Cell Cacinoma Drugs Revenue by Region (2017-2022)
2.5.2 Global Renal Cell Cacinoma Drugs Revenue by Region (2023-2028)
2.6 North America
2.7 Europe
2.8 Asia-Pacific
2.9 Latin America
2.10 Middle East & Africa
3 Competition by Manufacturers
3.1 Global Renal Cell Cacinoma Drugs Sales by Manufacturers
3.1.1 Global Top Renal Cell Cacinoma Drugs Manufacturers by Sales (2017-2022)
3.1.2 Global Renal Cell Cacinoma Drugs Sales Market Share by Manufacturers (2017-2022)
3.1.3 Global Top 10 and Top 5 Largest Manufacturers of Renal Cell Cacinoma Drugs in 2021
3.2 Global Renal Cell Cacinoma Drugs Revenue by Manufacturers
3.2.1 Global Renal Cell Cacinoma Drugs Revenue by Manufacturers (2017-2022)
3.2.2 Global Renal Cell Cacinoma Drugs Revenue Market Share by Manufacturers (2017-2022)
3.2.3 Global Top 10 and Top 5 Companies by Renal Cell Cacinoma Drugs Revenue in 2021
3.3 Global Renal Cell Cacinoma Drugs Sales Price by Manufacturers (2017-2022)
3.4 Analysis of Competitive Landscape
3.4.1 Manufacturers Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Renal Cell Cacinoma Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.4.3 Global Renal Cell Cacinoma Drugs Manufacturers Geographical Distribution
3.5 Mergers & Acquisitions, Expansion Plans
4 Market Size by Type
4.1 Global Renal Cell Cacinoma Drugs Sales by Type
4.1.1 Global Renal Cell Cacinoma Drugs Historical Sales by Type (2017-2022)
4.1.2 Global Renal Cell Cacinoma Drugs Forecasted Sales by Type (2023-2028)
4.1.3 Global Renal Cell Cacinoma Drugs Sales Market Share by Type (2017-2028)
4.2 Global Renal Cell Cacinoma Drugs Revenue by Type
4.2.1 Global Renal Cell Cacinoma Drugs Historical Revenue by Type (2017-2022)
4.2.2 Global Renal Cell Cacinoma Drugs Forecasted Revenue by Type (2023-2028)
4.2.3 Global Renal Cell Cacinoma Drugs Revenue Market Share by Type (2017-2028)
4.3 Global Renal Cell Cacinoma Drugs Price by Type
4.3.1 Global Renal Cell Cacinoma Drugs Price by Type (2017-2022)
4.3.2 Global Renal Cell Cacinoma Drugs Price Forecast by Type (2023-2028)
5 Market Size by Application
5.1 Global Renal Cell Cacinoma Drugs Sales by Application
5.1.1 Global Renal Cell Cacinoma Drugs Historical Sales by Application (2017-2022)
5.1.2 Global Renal Cell Cacinoma Drugs Forecasted Sales by Application (2023-2028)
5.1.3 Global Renal Cell Cacinoma Drugs Sales Market Share by Application (2017-2028)
5.2 Global Renal Cell Cacinoma Drugs Revenue by Application
5.2.1 Global Renal Cell Cacinoma Drugs Historical Revenue by Application (2017-2022)
5.2.2 Global Renal Cell Cacinoma Drugs Forecasted Revenue by Application (2023-2028)
5.2.3 Global Renal Cell Cacinoma Drugs Revenue Market Share by Application (2017-2028)
5.3 Global Renal Cell Cacinoma Drugs Price by Application
5.3.1 Global Renal Cell Cacinoma Drugs Price by Application (2017-2022)
5.3.2 Global Renal Cell Cacinoma Drugs Price Forecast by Application (2023-2028)
6 North America
6.1 North America Renal Cell Cacinoma Drugs Market Size by Type
6.1.1 North America Renal Cell Cacinoma Drugs Sales by Type (2017-2028)
6.1.2 North America Renal Cell Cacinoma Drugs Revenue by Type (2017-2028)
6.2 North America Renal Cell Cacinoma Drugs Market Size by Application
6.2.1 North America Renal Cell Cacinoma Drugs Sales by Application (2017-2028)
6.2.2 North America Renal Cell Cacinoma Drugs Revenue by Application (2017-2028)
6.3 North America Renal Cell Cacinoma Drugs Market Size by Country
6.3.1 North America Renal Cell Cacinoma Drugs Sales by Country (2017-2028)
6.3.2 North America Renal Cell Cacinoma Drugs Revenue by Country (2017-2028)
6.3.3 U.S.
6.3.4 Canada
7 Europe
7.1 Europe Renal Cell Cacinoma Drugs Market Size by Type
7.1.1 Europe Renal Cell Cacinoma Drugs Sales by Type (2017-2028)
7.1.2 Europe Renal Cell Cacinoma Drugs Revenue by Type (2017-2028)
7.2 Europe Renal Cell Cacinoma Drugs Market Size by Application
7.2.1 Europe Renal Cell Cacinoma Drugs Sales by Application (2017-2028)
7.2.2 Europe Renal Cell Cacinoma Drugs Revenue by Application (2017-2028)
7.3 Europe Renal Cell Cacinoma Drugs Market Size by Country
7.3.1 Europe Renal Cell Cacinoma Drugs Sales by Country (2017-2028)
7.3.2 Europe Renal Cell Cacinoma Drugs Revenue by Country (2017-2028)
7.3.3 Germany
7.3.4 France
7.3.5 U.K.
7.3.6 Italy
7.3.7 Russia
8 Asia Pacific
8.1 Asia Pacific Renal Cell Cacinoma Drugs Market Size by Type
8.1.1 Asia Pacific Renal Cell Cacinoma Drugs Sales by Type (2017-2028)
8.1.2 Asia Pacific Renal Cell Cacinoma Drugs Revenue by Type (2017-2028)
8.2 Asia Pacific Renal Cell Cacinoma Drugs Market Size by Application
8.2.1 Asia Pacific Renal Cell Cacinoma Drugs Sales by Application (2017-2028)
8.2.2 Asia Pacific Renal Cell Cacinoma Drugs Revenue by Application (2017-2028)
8.3 Asia Pacific Renal Cell Cacinoma Drugs Market Size by Region
8.3.1 Asia Pacific Renal Cell Cacinoma Drugs Sales by Region (2017-2028)
8.3.2 Asia Pacific Renal Cell Cacinoma Drugs Revenue by Region (2017-2028)
8.3.3 China
8.3.4 Japan
8.3.5 South Korea
8.3.6 India
8.3.7 Australia
8.3.8 Taiwan
8.3.9 Indonesia
8.3.10 Thailand
8.3.11 Malaysia
8.3.12 Philippines
9 Latin America
9.1 Latin America Renal Cell Cacinoma Drugs Market Size by Type
9.1.1 Latin America Renal Cell Cacinoma Drugs Sales by Type (2017-2028)
9.1.2 Latin America Renal Cell Cacinoma Drugs Revenue by Type (2017-2028)
9.2 Latin America Renal Cell Cacinoma Drugs Market Size by Application
9.2.1 Latin America Renal Cell Cacinoma Drugs Sales by Application (2017-2028)
9.2.2 Latin America Renal Cell Cacinoma Drugs Revenue by Application (2017-2028)
9.3 Latin America Renal Cell Cacinoma Drugs Market Size by Country
9.3.1 Latin America Renal Cell Cacinoma Drugs Sales by Country (2017-2028)
9.3.2 Latin America Renal Cell Cacinoma Drugs Revenue by Country (2017-2028)
9.3.3 Mexico
9.3.4 Brazil
9.3.5 Argentina
10 Middle East and Africa
10.1 Middle East and Africa Renal Cell Cacinoma Drugs Market Size by Type
10.1.1 Middle East and Africa Renal Cell Cacinoma Drugs Sales by Type (2017-2028)
10.1.2 Middle East and Africa Renal Cell Cacinoma Drugs Revenue by Type (2017-2028)
10.2 Middle East and Africa Renal Cell Cacinoma Drugs Market Size by Application
10.2.1 Middle East and Africa Renal Cell Cacinoma Drugs Sales by Application (2017-2028)
10.2.2 Middle East and Africa Renal Cell Cacinoma Drugs Revenue by Application (2017-2028)
10.3 Middle East and Africa Renal Cell Cacinoma Drugs Market Size by Country
10.3.1 Middle East and Africa Renal Cell Cacinoma Drugs Sales by Country (2017-2028)
10.3.2 Middle East and Africa Renal Cell Cacinoma Drugs Revenue by Country (2017-2028)
10.3.3 Turkey
10.3.4 Saudi Arabia
11 Company Profiles
11.1 Merck & Co., Inc.
11.1.1 Merck & Co., Inc. Corporation Information
11.1.2 Merck & Co., Inc. Overview
11.1.3 Merck & Co., Inc. Renal Cell Cacinoma Drugs Sales, Price, Revenue and Gross Margin (2017-2022)
11.1.4 Merck & Co., Inc. Renal Cell Cacinoma Drugs Product Model Numbers, Pictures, Descriptions and Specifications
11.1.5 Merck & Co., Inc. Recent Developments
11.2 Exelixis Inc
11.2.1 Exelixis Inc Corporation Information
11.2.2 Exelixis Inc Overview
11.2.3 Exelixis Inc Renal Cell Cacinoma Drugs Sales, Price, Revenue and Gross Margin (2017-2022)
11.2.4 Exelixis Inc Renal Cell Cacinoma Drugs Product Model Numbers, Pictures, Descriptions and Specifications
11.2.5 Exelixis Inc Recent Developments
11.3 Argus Therapeutics, Inc.
11.3.1 Argus Therapeutics, Inc. Corporation Information
11.3.2 Argus Therapeutics, Inc. Overview
11.3.3 Argus Therapeutics, Inc. Renal Cell Cacinoma Drugs Sales, Price, Revenue and Gross Margin (2017-2022)
11.3.4 Argus Therapeutics, Inc. Renal Cell Cacinoma Drugs Product Model Numbers, Pictures, Descriptions and Specifications
11.3.5 Argus Therapeutics, Inc. Recent Developments
11.4 Bristol-Myers Squibb
11.4.1 Bristol-Myers Squibb Corporation Information
11.4.2 Bristol-Myers Squibb Overview
11.4.3 Bristol-Myers Squibb Renal Cell Cacinoma Drugs Sales, Price, Revenue and Gross Margin (2017-2022)
11.4.4 Bristol-Myers Squibb Renal Cell Cacinoma Drugs Product Model Numbers, Pictures, Descriptions and Specifications
11.4.5 Bristol-Myers Squibb Recent Developments
11.5 Genentech
11.5.1 Genentech Corporation Information
11.5.2 Genentech Overview
11.5.3 Genentech Renal Cell Cacinoma Drugs Sales, Price, Revenue and Gross Margin (2017-2022)
11.5.4 Genentech Renal Cell Cacinoma Drugs Product Model Numbers, Pictures, Descriptions and Specifications
11.5.5 Genentech Recent Developments
11.6 Immatics Biotechnologies
11.6.1 Immatics Biotechnologies Corporation Information
11.6.2 Immatics Biotechnologies Overview
11.6.3 Immatics Biotechnologies Renal Cell Cacinoma Drugs Sales, Price, Revenue and Gross Margin (2017-2022)
11.6.4 Immatics Biotechnologies Renal Cell Cacinoma Drugs Product Model Numbers, Pictures, Descriptions and Specifications
11.6.5 Immatics Biotechnologies Recent Developments
11.7 AVEO Oncology
11.7.1 AVEO Oncology Corporation Information
11.7.2 AVEO Oncology Overview
11.7.3 AVEO Oncology Renal Cell Cacinoma Drugs Sales, Price, Revenue and Gross Margin (2017-2022)
11.7.4 AVEO Oncology Renal Cell Cacinoma Drugs Product Model Numbers, Pictures, Descriptions and Specifications
11.7.5 AVEO Oncology Recent Developments
11.8 Eisai
11.8.1 Eisai Corporation Information
11.8.2 Eisai Overview
11.8.3 Eisai Renal Cell Cacinoma Drugs Sales, Price, Revenue and Gross Margin (2017-2022)
11.8.4 Eisai Renal Cell Cacinoma Drugs Product Model Numbers, Pictures, Descriptions and Specifications
11.8.5 Eisai Recent Developments
11.9 Acceleron
11.9.1 Acceleron Corporation Information
11.9.2 Acceleron Overview
11.9.3 Acceleron Renal Cell Cacinoma Drugs Sales, Price, Revenue and Gross Margin (2017-2022)
11.9.4 Acceleron Renal Cell Cacinoma Drugs Product Model Numbers, Pictures, Descriptions and Specifications
11.9.5 Acceleron Recent Developments
11.10 Rexahn Pharmaceuticals
11.10.1 Rexahn Pharmaceuticals Corporation Information
11.10.2 Rexahn Pharmaceuticals Overview
11.10.3 Rexahn Pharmaceuticals Renal Cell Cacinoma Drugs Sales, Price, Revenue and Gross Margin (2017-2022)
11.10.4 Rexahn Pharmaceuticals Renal Cell Cacinoma Drugs Product Model Numbers, Pictures, Descriptions and Specifications
11.10.5 Rexahn Pharmaceuticals Recent Developments
11.11 Bionomics
11.11.1 Bionomics Corporation Information
11.11.2 Bionomics Overview
11.11.3 Bionomics Renal Cell Cacinoma Drugs Sales, Price, Revenue and Gross Margin (2017-2022)
11.11.4 Bionomics Renal Cell Cacinoma Drugs Product Model Numbers, Pictures, Descriptions and Specifications
11.11.5 Bionomics Recent Developments
11.12 Cerulean Pharma Inc
11.12.1 Cerulean Pharma Inc Corporation Information
11.12.2 Cerulean Pharma Inc Overview
11.12.3 Cerulean Pharma Inc Renal Cell Cacinoma Drugs Sales, Price, Revenue and Gross Margin (2017-2022)
11.12.4 Cerulean Pharma Inc Renal Cell Cacinoma Drugs Product Model Numbers, Pictures, Descriptions and Specifications
11.12.5 Cerulean Pharma Inc Recent Developments
11.13 Celldex Therapeutics
11.13.1 Celldex Therapeutics Corporation Information
11.13.2 Celldex Therapeutics Overview
11.13.3 Celldex Therapeutics Renal Cell Cacinoma Drugs Sales, Price, Revenue and Gross Margin (2017-2022)
11.13.4 Celldex Therapeutics Renal Cell Cacinoma Drugs Product Model Numbers, Pictures, Descriptions and Specifications
11.13.5 Celldex Therapeutics Recent Developments
11.14 TVAX Biomedical
11.14.1 TVAX Biomedical Corporation Information
11.14.2 TVAX Biomedical Overview
11.14.3 TVAX Biomedical Renal Cell Cacinoma Drugs Sales, Price, Revenue and Gross Margin (2017-2022)
11.14.4 TVAX Biomedical Renal Cell Cacinoma Drugs Product Model Numbers, Pictures, Descriptions and Specifications
11.14.5 TVAX Biomedical Recent Developments
11.15 TRACON Pharmaceuticals
11.15.1 TRACON Pharmaceuticals Corporation Information
11.15.2 TRACON Pharmaceuticals Overview
11.15.3 TRACON Pharmaceuticals Renal Cell Cacinoma Drugs Sales, Price, Revenue and Gross Margin (2017-2022)
11.15.4 TRACON Pharmaceuticals Renal Cell Cacinoma Drugs Product Model Numbers, Pictures, Descriptions and Specifications
11.15.5 TRACON Pharmaceuticals Recent Developments
12 Industry Chain and Sales Channels Analysis
12.1 Renal Cell Cacinoma Drugs Industry Chain Analysis
12.2 Renal Cell Cacinoma Drugs Key Raw Materials
12.2.1 Key Raw Materials
12.2.2 Raw Materials Key Suppliers
12.3 Renal Cell Cacinoma Drugs Production Mode & Process
12.4 Renal Cell Cacinoma Drugs Sales and Marketing
12.4.1 Renal Cell Cacinoma Drugs Sales Channels
12.4.2 Renal Cell Cacinoma Drugs Distributors
12.5 Renal Cell Cacinoma Drugs Customers
13 Market Drivers, Opportunities, Challenges and Risks Factors Analysis
13.1 Renal Cell Cacinoma Drugs Industry Trends
13.2 Renal Cell Cacinoma Drugs Market Drivers
13.3 Renal Cell Cacinoma Drugs Market Challenges
13.4 Renal Cell Cacinoma Drugs Market Restraints
14 Key Findings in The Global Renal Cell Cacinoma Drugs Study
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Author Details
15.3 Disclaimer